Healthcare entity
medical-devices is the sole category represented across all 1 tracked stories. Of the tracked stories, 1 of 1 also mention Citigroup, the most common co-covered peer. Robert W. Baird appears in 1 tracked Healthcare story from July 10, 2026. The tracked stories average 2 original sources each.
Last mentioned: 3d ago
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
medical-devices is the sole category represented across all 1 tracked stories. Of the tracked stories, 1 of 1 also mention Citigroup, the most common co-covered peer. Robert W. Baird appears in 1 tracked Healthcare story from July 10, 2026. The tracked stories average 2 original sources each.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 2 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Robert W. Baird. Shared-story counts are live from our verified record — not editorial picks.
Analyst downgrades reflect growing fears that GLP-1 weight loss drugs could erode the sleep apnea device market, even as ResMed’s financials stay solid. The contrast between a $225 low target and $321 high target underscores sector uncertainty.
Robert W. Baird is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
